Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
NCT ID: NCT02502162
Last Updated: 2025-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2015-06-30
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
NCT06306157
Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy
NCT04678895
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
NCT00067743
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
NCT00109772
Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain
NCT01415895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LDN
Naltrexone HCL, 4.5 mg, Once a day.
LDN
Placebo
Sugar pill
Placebo
Sugar pill
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LDN
Placebo
Sugar pill
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On stable treatment for 1 month
* CRPS for at least 1 year
* Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria
* Use of prescription opioid analgesics or illegal opioid use
* Current or planned pregnancy.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sean Mackey
Redlich Professor Departments of Anesthesiology, Perioperative and Pain Medicine | Neurosciences | Neurology (by courtesy), Chief, Division of Pain Medicine, Director, Stanford Systems Neuroscience and Pain Lab (SNAPL), Stanford University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sean Mackey, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
33607
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.